For children diagnosed with brain tumors, tissue biopsies carry serious neurological risk — yet without molecular tumor profiling, treatment personalization remains guesswork. A new prospective clinical study demonstrates that cerebrospinal fluid can serve as a practical, less invasive alternative, yielding actionable genomic data that tracks disease course and distinguishes relapse from a new malignancy — a distinction with profound treatment implications.
The study analyzed 148 CSF samples from 120 pediatric patients using droplet digital PCR and next-generation sequencing. Tumor-derived cell-free DNA was detected in 54% of samples overall, but detection rates varied significantly by tumor grade and sample source. High-grade gliomas at diagnosis achieved 100% ctDNA positivity, while low-grade gliomas reached 50%. Ventricular sampling outperformed lumbar puncture — 65% versus 45% ctDNA positivity, respectively — a finding with direct procedural implications. Among low-grade gliomas, dissemination was associated with higher detection rates (80% versus 43% in localized cases). The assay also quantified mismatch-repair deficiency signatures directly from CSF, supporting active disease identification in a notoriously difficult-to-monitor tumor subtype.
This work sits at a critical juncture in pediatric neuro-oncology. Liquid biopsy has been validated extensively in adult solid tumors, but CNS applications remain technically challenging due to low ctDNA shedding into peripheral blood. CSF bypasses that barrier by sampling a compartment anatomically proximate to the tumor. The 54% overall detection rate, while meaningful, underscores a persistent limitation: nearly half of samples yield no signal, meaning a negative result cannot rule out active disease. The ventricular-versus-lumbar detection gap also raises a practical concern — ventricular access typically requires surgical intervention, partially offsetting the minimally invasive advantage. As a prospective real-world study rather than a randomized trial, causality cannot be inferred. Still, the ability to serially track ctDNA levels through treatment represents an incremental but clinically meaningful advance, particularly for children where repeated tissue sampling carries disproportionate risk.